Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review)
International Journal of Oncology · 2024
DOI: 10.3892/ijo.2024.5676 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, 2024. Verfasst von Shenghao Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Transcription Factors, Signal Transduction. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 248 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The Hippo signaling pathway plays a pivotal role in regulating cell growth and organ size. Its regulatory effects on hepatocellular carcinoma (HCC) encompass diverse aspects, including cell proliferation, invasion and metastasis, tumor drug resistance, metabolic reprogramming, immunomodulatory effects and autophagy. Yes‑associated protein 1 (YAP1), a potent transcriptional coactivator and a major downstream target tightly controlled by the Hippo pathway, is influenced by various molecules and pathways. The expression of YAP1 in different cell types within the liver tumor microenvironment exerts varying effects on tumor outcomes, warranting careful consideration. Therefore, research on YAP1‑targeted therapies merits attention. This review discusses the composition and regulation mechanism of the Hippo/YAP1 signaling pathway and its relationship with HCC, offering insights for future research and cancer prevention strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, P.R. China.
- Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China.
- Clinical Research Center, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei 050024, P.R. China.
- Center of Experimental Management, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, P.R. China.
Zitieren
APA
Li, S., Hao, L., Li, N., Hu, X., Yan, H., Dai, E., & Shi, X. (2024). Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review). International Journal of Oncology. https://doi.org/10.3892/ijo.2024.5676
Vancouver
Li S, Hao L, Li N, Hu X, Yan H, Dai E, et al. Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review). International Journal of Oncology. 2024. doi:10.3892/ijo.2024.5676
BibTeX
@article{Li2024,
author = {Li, Shenghao and Hao, Liyuan and Li, Na and Hu, Xiaoyu and Yan, Huimin and Dai, Erhei and Shi, Xinli},
title = {Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review)},
journal = {International Journal of Oncology},
year = {2024},
doi = {10.3892/ijo.2024.5676}
}
EUVIMED